Benitec Biopharma Ltd Stock Performance
| BNTC Stock | USD 10.09 0.36 3.70% |
On a scale of 0 to 100, Benitec Biopharma holds a performance score of 4. The firm shows a Beta (market volatility) of 0.15, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Benitec Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Benitec Biopharma is expected to be smaller as well. Please check Benitec Biopharma's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Benitec Biopharma's price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Benitec Biopharma Ltd are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent basic indicators, Benitec Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.7 | Five Day Return (3.72) | Year To Date Return 208.56 | Ten Year Return (99.67) | All Time Return (99.83) |
Last Split Factor 1:17 | Dividend Date 2019-11-18 | Last Split Date 2023-07-26 |
1 | Benitec Biopharma approves equity plan amendment - Investing.com | 09/05/2024 |
2 | Piper Sandler maintains price target on Benitec BioPharma shares - Investing.com | 09/24/2024 |
3 | Suvretta Capital Managements Strategic Acquisition in Benitec Biopharma Inc - Yahoo Finance | 09/30/2024 |
4 | Benitec Biopharma Receives Market Outperform Rating from JMP Securities | 10/04/2024 |
5 | Wells Fargo To Rally Around 16 Here Are 10 Top Analyst Forecasts For Monday | 10/14/2024 |
6 | Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference | 11/04/2024 |
7 | Acquisition by Suvretta Capital Management, Llc of 1570 shares of Benitec Biopharma at 9.73 subject to Rule 16b-3 | 11/19/2024 |
8 | Acquisition by Suvretta Capital Management, Llc of 3076 shares of Benitec Biopharma at 10.22 subject to Rule 16b-3 | 11/20/2024 |
9 | Benitec Biopharma to Participate in Upcoming Investor Conferences in December | 11/26/2024 |
| Begin Period Cash Flow | 2.5 M |
Benitec |
Benitec Biopharma Relative Risk vs. Return Landscape
If you would invest 898.00 in Benitec Biopharma Ltd on September 1, 2024 and sell it today you would earn a total of 111.00 from holding Benitec Biopharma Ltd or generate 12.36% return on investment over 90 days. Benitec Biopharma Ltd is currently generating 0.2928% in daily expected returns and assumes 4.7754% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Benitec, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Benitec Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Benitec Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Benitec Biopharma Ltd, and traders can use it to determine the average amount a Benitec Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0613
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BNTC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.78 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Benitec Biopharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Benitec Biopharma by adding it to a well-diversified portfolio.
Benitec Biopharma Fundamentals Growth
Benitec Stock prices reflect investors' perceptions of the future prospects and financial health of Benitec Biopharma, and Benitec Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Benitec Stock performance.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.5 | ||||
| Current Valuation | 166.62 M | ||||
| Shares Outstanding | 19.82 M | ||||
| Price To Earning | (5.10) X | ||||
| Price To Book | 3.65 X | ||||
| Price To Sales | 2,770 X | ||||
| Revenue | 216 K | ||||
| Gross Profit | 75 K | ||||
| EBITDA | (22.49 M) | ||||
| Net Income | (21.75 M) | ||||
| Cash And Equivalents | 4.06 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 284 K | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 4.68 X | ||||
| Cash Flow From Operations | (19.4 M) | ||||
| Earnings Per Share | (5.51) X | ||||
| Market Capitalization | 215.39 M | ||||
| Total Asset | 52.21 M | ||||
| Retained Earnings | (190.26 M) | ||||
| Working Capital | 46.75 M | ||||
| Current Asset | 19.38 M | ||||
| Current Liabilities | 1.03 M | ||||
About Benitec Biopharma Performance
By analyzing Benitec Biopharma's fundamental ratios, stakeholders can gain valuable insights into Benitec Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Benitec Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Benitec Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 14.32 | 13.61 | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.46) | (0.48) |
Things to note about Benitec Biopharma performance evaluation
Checking the ongoing alerts about Benitec Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Benitec Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Benitec Biopharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Benitec Biopharma to Participate in Upcoming Investor Conferences in December |
- Analyzing Benitec Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Benitec Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Benitec Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Benitec Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Benitec Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Benitec Biopharma's stock. These opinions can provide insight into Benitec Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Benitec Stock analysis
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |